Xeris Biopharma Q4 2025 Earnings Call Summary

1Key Financial Results and Metrics

Q4 Revenue:: $85.8 million, up 43% year-over-year.

Full Year Revenue:: $291.8 million, a 44% increase compared to 2024.

Adjusted EBITDA:: Q4 at $25.1 million; full year at $59.4 million.

Net Income:: Reported for the first time on a full-year basis.

Gross Margin:: 87% for Q4 and 85% for the full year, reflecting improved product mix.

2Strategic Updates and Business Highlights

Product Performance::

Recorlev:: Revenue of $45.3 million in Q4, more than 100% growth year-over-year. Patient base nearly doubled to approximately 700.

Gvoke:: Revenue of $24.6 million in Q4, with steady growth driven by broad access and prescriber awareness.

Keveyis:: Revenue of $12.8 million in Q4, continuing to outperform expectations.

Commercial Expansion:: Nearly doubled the Recorlev commercial team to enhance healthcare provider and patient interactions.

Legal Actions:: Filed a patent infringement lawsuit against two ANDA filers to protect Recorlev's market position.

3Forward Guidance and Outlook

2026 Revenue Guidance:: Expected between $375 million and $390 million, representing over 30% growth at the midpoint compared to 2025.

Adjusted EBITDA:: Anticipated to remain positive, with growth in absolute dollars.

R&D Investments:: Expected increase of approximately $25 million to support XP-8121 Phase III initiation in H2 2026.

SG&A Expenses:: Projected increase of about $45 million to support Recorlev's growth.

4Bad News, Challenges, or Points of Concern

Competitive Pressures:: Concerns regarding potential competition from generic versions of Korlym, although management expressed confidence that it would not significantly impact Recorlev.

IP Litigation:: Ongoing patent infringement lawsuit could introduce uncertainty, although management remains confident in their legal position.

Market Dynamics:: The first quarter typically experiences payer resets that may temporarily slow growth.

5Notable Q&A Insights

Sales Force Expansion:: Management indicated that the recent doubling of the commercial team is crucial for sustaining growth and managing patient loads.

Capital Deployment:: Discussions around future capital allocation suggest a focus on internal growth opportunities, with potential for external business development if advantageous.

XP-8121 Development:: No regulatory gating items for the Phase III trial, but emphasis on ensuring readiness with a go-to-market device.

Market Strategy:: Management remains committed to their long-term strategy for Recorlev, with expectations of reaching $1 billion in peak sales by 2035. Overall, Xeris Biopharma demonstrated strong financial performance in 2025, marked by significant revenue growth and a shift to profitability, while strategically positioning itself for continued expansion and development in 2026.